ClinicalTrials.Veeva

Menu

Predictors of Reactive Thrombocytosis in Critically Ill Septic Patients

S

Sanjay Gandhi Postgraduate Institute of Medical Sciences

Status

Unknown

Conditions

Critically Ill
Thrombocytosis
Sepsis

Study type

Observational

Funder types

Other

Identifiers

NCT03531515
2018-26-MD-EXP

Details and patient eligibility

About

Reactive or secondary thrombocytosis is defined as abnormally high platelet count (≥4,50,000 platelets per micro-liter) in the absence of chronic myeloproliferative disease. In critically ill patients reactive thrombocytosis is not uncommon during recovery phase and an association has been seen with poor outcome and increased risk of subsequent VTE. However, not all patients with infection respond with thrombocytosis. No study has enumerated the risk factors or predictors of reactive thrombocytosis in critically ill septic patients.

Full description

All patients admitted to intensive care unit of the department of Critical Care Medicine during one year period will be screened for possible inclusion in this study. In this prospective observational study, demographic and clinical characteristics of all ICU patients who fulfill inclusion criteria will be collected along with relevant laboratory tests done for patient management routinely. ICU prognostication scores, i.e., Acute Physiologic and Chronic Health Evaluation (APACHE) II score and Sequential Organ Failure Assessment (SOFA) score will also be recorded. ICU survivors will be followed up in their routine ICU follow up clinic visits.

Sample size was estimated at 10% incidence rate of reactive thrombocytes, two sided 95% confidence interval and 4.5% margin of error of the incidence rate, sample size came out to be 171. Finally in this study investigators have targeted to include at least 180 participants. Sample size was estimated using software power analysis and sample size, 2008 (PASS-8).

Enrollment

200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All adult (≥18 years) ICU patients with the diagnosis of sepsis will be considered.

Exclusion criteria

  • Age <18 years
  • Pregnancy
  • H/O Malignancy
  • Thrombocytosis at admission
  • Primary thrombocytosis
  • Post-splenectomy
  • Chronic inflammatory disease (e.g. Connective tissue disorders, IBD, temporal arteritis)
  • Known immunosupressive condition
  • Chronic infectious diseases (e.g. tuberculosis, chronic pneumonitis)

Trial contacts and locations

1

Loading...

Central trial contact

Mohan Gurjar, MD, PDCC; Monalisa Nayak, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems